Objectives To estimate the risk of venous thromboembolism (VTE) in a nationwide cohort of newly diagnosed patients with SLE ...

Objectives CD163 is a macrophage-associated scavenger receptor shed during inflammatory activation, resulting in measurable ...

Objective Belimumab has been proven to be effective for treating refractory lupus nephritis. However, the meaningful renal ...

Objective Childhood-onset SLE (cSLE) is often described as more severe than adult-onset disease (aSLE) based largely on cross ...

Objective Fibromyalgia (FM) frequently co-occurs with SLE, but its independent contribution to musculoskeletal risk is unclear. We aimed to determine whether comorbid FM is independently associated ...

Introduction Cognitive symptoms such as ‘brain fog’ are frequent and disabling in patients with SLE. We aimed to develop and validate the Lupus Brain Fog Severity Scale (LBFSS), the first ...

Objective SLE is a chronic autoimmune disorder with a range of symptoms. While these are broadly reported in the literature, the symptom impact of SLE on patient health-related quality of life is less ...

Objective This analysis describes disease activity, organ damage and health-related quality of life (HRQoL) in patients with active SLE and moderate-to-severe disease activity from the Spanish SLE ...

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist. Clinical trials in SLE have not consistently demonstrated an increased ...

Objective To evaluate the feasibility and safety of belimumab dose spacing and withdrawal in patients with SLE in long-standing remission on belimumab. Methods Patients with SLE fulfilling the 2019 ...